These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 19210206

  • 1. Focus on ivabradine: a new heart rate-controlling drug.
    Riccioni G.
    Expert Rev Cardiovasc Ther; 2009 Feb; 7(2):107-13. PubMed ID: 19210206
    [Abstract] [Full Text] [Related]

  • 2. Ivabradine: beyond heart rate control.
    Riccioni G, Vitulano N, D'Orazio N.
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [Abstract] [Full Text] [Related]

  • 3. Ivabradine: new drug. Best avoided in stable angina.
    Prescrire Int; 2007 Apr; 16(88):53-6. PubMed ID: 17458043
    [Abstract] [Full Text] [Related]

  • 4. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N, Bhargava B.
    Am J Cardiovasc Drugs; 2011 Apr; 11(1):1-12. PubMed ID: 21090826
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Ivabradine for stable angina?
    Drug Ther Bull; 2008 Nov; 46(11):84-8. PubMed ID: 18987382
    [Abstract] [Full Text] [Related]

  • 7. Ivabradine: pharmacodynamic aspects of its clinical use.
    Stieber J.
    Methods Find Exp Clin Pharmacol; 2008 Oct; 30(8):633-41. PubMed ID: 19088948
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Heart rate slowing versus other pharmacological antianginal strategies.
    Diaz A, Tardif JC.
    Adv Cardiol; 2006 Oct; 43():65-78. PubMed ID: 16936473
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.
    Rousseau MF, Pouleur H, Cocco G, Wolff AA.
    Am J Cardiol; 2005 Feb 01; 95(3):311-6. PubMed ID: 15670536
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus.
    Borer JS, Tardif JC.
    Am J Cardiol; 2010 Jan 01; 105(1):29-35. PubMed ID: 20102886
    [Abstract] [Full Text] [Related]

  • 17. Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study.
    Müller-Werdan U, Stöckl G, Ebelt H, Nuding S, Höpfner F, Werdan K, ADDITIONS Study Investigators.
    Exp Gerontol; 2014 Nov 01; 59():34-41. PubMed ID: 25193811
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety and efficacy of ivabradine in patients with chronic stable angina.
    López-Bescós L, Filipova S, Martos R.
    Cardiology; 2007 Nov 01; 108(4):387-96. PubMed ID: 17890862
    [Abstract] [Full Text] [Related]

  • 19. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine.
    Doesch AO, Celik S, Ehlermann P, Frankenstein L, Zehelein J, Koch A, Katus HA, Dengler TJ.
    Transplantation; 2007 Oct 27; 84(8):988-96. PubMed ID: 17989604
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.